FDA’s Big Mistake: Expect Flibanserin to Be Pulled From the Market in a Few Years
FDA’s Big Mistake: Expect Flibanserin to Be Pulled From the Market in a Few Years
August 19, 2015
The U.S. Food and Drug Administration’s (FDA’s) decision to approve flibanserin as a treatment for women with hypoactive sexual desire presents serious dangers to women, with little benefit, and recklessly disregards the worrisome risk information in the agency’s briefing package to the advisory committees that met on June 4 to review the drug.